

**Amendments to the Specification:**

***Please replace paragraph [0001] with the following amended paragraph:***

**[0001]** This application is a continuation of U.S. Application No. 09/723,544, filed November 28, 2000, now abandoned, which is a continuation of U.S. Application No. 09/580,018, filed ~~May 26, 2000.~~ ~~May 26, 2000, which is a continuation in part of U.S. Application No. 09/322,289, filed May 28, 1999, which is a continuation in part of U.S. Application No. 09/201,430, filed November 30, 1998, which claims the benefit under 35 U.S.C. § 119(e) of U.S. Application No. 60/080,970, filed April 7, 1998.~~ U.S. Application No. 09/580,018, filed May 26, 2000 is incorporated herein by reference in its entirety for all purposes.

***Please replace paragraph [0126] with the following amended paragraph:***

**[0126]** Some agents for inducing an immune response contain the appropriate epitope for inducing an immune response against amyloid deposits but are too small to be immunogenic. In this situation, a peptide immunogen can be linked to a suitable carrier to help elicit an immune response. Suitable carriers include serum albumins, keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid, or a toxoid from other pathogenic bacteria, such as diphtheria (e.g., CRM197), *E. coli*, cholera, or *H. pylori*, or an attenuated toxin derivative. Other carriers include T-cell epitopes that bind to multiple MHC alleles, e.g., at least 75% of all human MHC alleles. Such carriers are sometimes known in the art as “universal T-cell epitopes.” Examples of universal T-cell epitopes include:

Influenza Hemagglutinin: HA<sub>307-319</sub> PKYVKQNTLKLAT (SEQ ID NO:43)

PADRE (common residues bolded) AKXVAAW**TL**KAAA (SEQ ID NO:44)

Malaria CS: T3 epitope EK**K**IAKMEKASSVFNV (SEQ ID NO:45)

Hepatitis B surface antigen: HBsAg<sub>19-28</sub> F**F**LLTRILTI (SEQ ID NO:46)

Heat Shock Protein 65: hsp65<sub>153-171</sub> DQSIGDLIAEAMDKVGNEG (SEQ ID NO:47)

bacille Calmette-Guerin QVHFQPLPPAVV**K**L (SEQ ID NO:48)

Application No. 10/777,792

PATENT

Amendment dated October 30, 2007

Reply to Final Office Action of May 8, 2007

Amendment under 37 CFR 1.116 Expedited Procedure Examining Group 1649

Tetanus toxoid: TT<sub>830-844</sub> QYIKANSKFIGITEL (SEQ ID NO:49)

Tetanus toxoid: TT<sub>947-967</sub> FNNFTVSFWLRVPKVSASHLE (SEQ ID NO:50)

HIV gp120 T1: KQIINMWQEVGKAMYA (SEQ ID NO:51).